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Abstract
We have investigated the presence of diazoxide- and nicorandil-activated K+ channels in rat skeletal muscle. Activation of potassium
transport in the rat skeletal muscle myoblast cell line L6 caused a stimulation of cellular oxygen consumption, implying a mitochondrial
effect. Working with isolated rat skeletal muscle mitochondria, both potassium channel openers (KCOs) stimulate respiration, depolarize the
mitochondrial inner membrane and lead to oxidation of the mitochondrial NAD-system in a strict potassium-dependent manner. This is a
strong indication for KCO-mediated stimulation of potassium transport at the mitochondrial inner membrane. Moreover, the potassium-
specific effects of both diazoxide and nicorandil on oxidative phosphorylation in skeletal muscle mitochondria were completely abolished by
the antidiabetic sulfonylurea derivative glibenclamide, a well-known inhibitor of ATP-regulated potassium channels (KATP channels). Since
both diazoxide and nicorandil facilitated swelling of de-energised mitochondria in KSCN buffer at the same concentrations, our results
implicate the presence of a mitochondrial ATP-regulated potassium channel (mitoKATP channel) in rat skeletal muscle which can modulate
mitochondrial oxidative phosphorylation.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
ATP-regulated potassium channels (KATP channels) were
originally discovered in the plasma membrane of cardiac
muscle cells [1]. These channels have also been described in
other tissues and they couple cellular energetic level to the
plasma membrane potential (for a review, see Refs. [2,3]).
The KATP channels are regulated by antidiabetic sulfonylur-
eas such as glibenclamide or glipizide, and potassium
channel openers (KCOs) such as diazoxide or pinacidil
[4,5]. The molecular composition of plasma membrane
KATP channels has been recently clarified. The channels
are heterooctamers of four inwardly rectifying K+ pore
subunits and four sulfonylureas receptors (SURs). Two
members of Kir family, Kir6.1 and Kir6.2, appear to be
capable of forming a KATP channel. Additionally, these
subunits have to co-assemble with SURs encoded by either
of two genes, SUR1 or SUR2, to form a functional KATP
channel.
In 1991, a mitochondrial ATP-regulated potassium chan-
nel (mitoKATP channel) was identified by patch-clamp
single-channel recordings in the inner membrane of liver
mitochondria [6]. Later on, a similar channel was described
in heart [7], and brain mitochondria [8,9]. Similarly to the
plasma membrane KATP channel, the mitochondrial channel
is inhibited by antidiabetic sulfonylureas and activated by
KCOs. Especially diazoxide seems to be potent activator of
the mitoKATP channel [10]. The primary function of this
channel is to allow K+ transport into the mitochondrial
matrix. This phenomenon could be involved in maintenance
of mitochondrial volume homeostasis. Additionally, the
cardiac mitoKATP channel plays an important role in pro-
tecting cardiomyocytes during ischemia/reperfusion (for a
review, see Refs. [11–13]).
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The molecular identity of the mitoKATP channel is
unknown. Several observations on the pharmacological
profile may suggest that the mitoKATP channel belongs to
the inward rectifier K+ channel family—Kir6.x [14,15].
Similarly, the molecular properties of mitochondrial SURs
are not clear. The usage of 125I-glibenclamide led to labeling
of a 28-kDa protein in heart mitochondria [16]. Recently,
with the use of the fluorescent probe BODIPY-glibencla-
mide, a 64-kDa protein was labeled in brain mitochondria
[9]. A recent report [17], noticed 10-hydroxydecanoate-
sensitive uncoupling effects of diazoxide in C2C12 skeletal
myotubes which might suggest the presence of a mitoKATP
channel also in skeletal muscle.
In the present work, we have analyzed in detail the
effects of KCOs on L6 skeletal myoblast cell line and
isolated rat skeletal muscle mitochondria. We show that
activation of potassium transport in rat skeletal muscle
myoblast cell line L6 by KCOs such as diazoxide and
nicorandil caused a stimulation of cellular oxygen con-
sumption implying a mitochondrial effect of these drugs.
Further we investigated the effect of KCOs on the
function of isolated rat skeletal muscle mitochondria.
We observed that both openers stimulate respiration,
depolarize the mitochondria, lead to oxidation of the
mitochondrial NAD-system and facilitate swelling of de-
energised mitochondria in a KSCN buffer. All effects
were measured in strict potassium-dependent manner, that
is, the presence of K+ ions was obligatory to observe
these effects. Moreover, the activation of potassium trans-
port in skeletal muscle mitochondria by both diazoxide
Fig. 1. Effect of KCOs on the oxygen consumption of the L6 myoblast cell line. (A) Stimulation of L6 cell respiration by diazoxide. 1–1.5 105 L6 cells were
added into 1.5 ml of the medium for cellular respiration measurements (Materials and Methods). Additions: glucose—10 mM, glutamine—10 mM,
diazoxide—60 AM, TTFB—1.5 AM (two additions). (B) Effect of glibenclamide on the stimulation of L6 cell respiration by diazoxide. Additions like in A,
when indicated 20 AM glibenclamide was added. (C) Potassium opener concentration dependency of L6 myoblast cell line respiration rates. Experimental
conditions like in the legend to A. The experimental points are averagesF S.D. of four independent experiments performed with two different cell line batches.
Filled circles—diazoxide, filled triangles—nicorandil. (D) Valinomycin concentration dependency of L6 myoblast cell line respiration rates. Experimental
conditions like in the legend to A. The experimental points are averagesF S.D. of two independent experiments.
G. Debska et al. / Biochimica et Biophysica Acta 1556 (2002) 97–10598
and nicorandil was inhibited by glibenclamide, a well-
known inhibitor of KATP channels. Our data strongly
suggest the presence of a mitoKATP channel in skeletal
muscle mitochondria.
2. Materials and methods
2.1. Isolation of mitochondria
The mitochondria from about 1 g of total hindlimb
skeletal muscle from one rat were isolated according to a
previously described procedure [18]. Using 10 mM gluta-
mate and 5 mM malate as substrates, respiratory control
ratios higher than 6 were routinely obtained.
2.2. Cell culture
Skeletal myoblast cell line L6 (kindly provided by Dr. A.
Orzechowski) was routinely cultured in DMEM medium
supplemented with 10% heat-inactivated FCS, 4 mM glu-
tamine, 100 units/ml penicillin, and 100 Ag/ml streptomy-
cin. The cells were incubated in an atmosphere containing
5% CO2/95% air at 37 jC.
2.3. Respiration measurements
The oxygen consumption of mitochondria was measured
at 30 jC using an Oroboros oxygraph (Anton Paar, Graz) in
a medium containing 5 mM MgCl2, 60 mM KCl, 100 mM
mannitol, 10 mM KH2PO4, 0.5 mM Na2EDTA and 60 mM
Tris–HCl (pH 7.4). For uncoupling of oxidative phosphor-
ylation, we used 4,5,6,7-tetrachloro-2-trifluoromethylbenzi-
midazole (TTFB) a kind gift of B. Beechey (University of
Wales, Aberystwyth, UK).
2.4. Mitochondrial membrane potential
The measurements were made at 25 jC in a 1-ml cuvette
of a Shimadzu RF-5000 spectrofluorimeter (Tokyo, Japan)
using 2 AM of the membrane potential sensitive fluorescent
dye rhodamine 123 [19], in a medium containing 5 mM
MgCl2, 60 mM KCl, 100 mM mannitol, 10 mM KH2PO4,
0.5 mM Na2EDTA and 60 mM Tris–HCl (pH 7.4). The
protein concentration of the mitochondrial suspension was
1–2 mg/ml. The samples were excited at 450 nm and the
rhodamine 123 fluorescence was registered at 520 nm. To
calculate the mitochondrial membrane potential, the fluo-
rescence changes were calibrated using potassium diffusion
potentials. For this, 2 Ag/ml valinomycin was added to the
rotenone-de-energised mitochondrial preparation incubated
in the medium in which K+ was replaced by Na+. Thereafter,
defined additions of KCl were made until no changes of
rhodamine 123 fluorescence were recorded (equilibrium
point). The corresponding potentials were calculated with
the Nernst equation.
2.5. NADP(H) fluorescence
For the measurements of fluorescence of NAD(P)H,
about 6 mg mitochondria was incubated in the medium
used for the oxygraphic measurements. The measurements
were made at 25 jC in a 1-ml cuvette of a Shimadzu RF-
5000 spectrofluorimeter (Tokyo, Japan) using 340 nm
excitation and 450 nm emission for NAD(P)H [20].
2.6. Measurements of mitochondrial volume changes
The kinetics of light scattering of de-energised mito-
chondria, reflecting volume changes linked to solute
transport, were determined following the decrease of
absorption of the suspension at 540 nm at 30 jC. The
Fig. 2. Effects of KCOs on the respiration of isolated skeletal muscle
mitochondria. (A) Stimulation of mitochondrial respiration by diazoxide.
Two milligrams of rat skeletal muscle mitochondria (RSM) was added into
1.5 ml of the medium for mitochondrial respiration measurements (see
Materials and Methods) containing additionally 10 mM glutamate and 5
mM malate. Additions: diazoxide—100 AM, ADP—2 mM. (B) Potassium
opener concentration dependency of rat skeletal muscle mitochondria
respiration rates. Experimental conditions like in the legend to A. The
experimental points are averagesF S.D. of six independent experiments
performed with three different mitochondrial preparations. Filled circles—
diazoxide, filled triangles—nicorandil.
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measurements were performed at a protein concentration
of 3 mg/ml in a medium containing 150 mM KSCN, 20
mM Hepes–KOH (pH 7.4) and 1 AM rotenone.
3. Results
Since skeletal muscle fibers and in particular the rat
skeletal myoblast cell line L6 contain in the plasma
membrane potassium channels, but similar to heart muscle
also might contain a mitochondrial potassium channel, we
have evaluated the bioenergetic consequences of the
application of KCOs. An overview of the action of KCOs
on the L6 cell line is given in Fig. 1. As shown in panel
A, the addition of 60 AM diazoxide stimulated the
respiration rate of glucose + glutamine oxidizing L6 cells
about two times. This effect of the drug is very unlikely
related to its action on plasma membrane channels since a
hyperpolarization of the plasma membrane should sup-
press respiration due to the decreased ATP turnover. On
the other hand, the addition of 20 AM glibenclamide was
able to inhibit the stimulatory action of diazoxide on L6
cell respiration (Fig. 1, panel B). This observation indi-
cates that the effect of diazoxide is most likely related to
Fig. 3. Effects of KCOs on the membrane potential of isolated skeletal muscle mitochondria. (A) Mitochondrial membrane depolarization by diazoxide in a
potassium-containing medium. Two milligrams of rat skeletal muscle mitochondria (RSM) was added into 1 ml of the potassium-containing medium for
mitochondrial respiration measurements (Materials and Methods) containing additionally 10 mM glutamate, 5 mM malate and 2 AM rhodamine 123.
Additions: diazoxide (five additions)—10, 30, 50, 50 and 50 AM; valinomycin (valino)—10 nM; TTFB—1.3 AM. (B) Mitochondrial membrane depolarization
by diazoxide in a sodium-containing medium. Two milligrams rat skeletal muscle mitochondria (RSM) was added into 1 ml of the sodium-containing medium
for mitochondrial respiration measurements (Materials and Methods) containing additionally 10 mM glutamate, 5 mM malate and 2 AM rhodamine 123.
Additions like in A. (C) Potassium opener concentration dependency of rat skeletal muscle mitochondria potassium-specific membrane depolarization.
Experimental conditions like in the legends to A and B. The experimental points are averagesF S.D. of differences of membrane potentials determined in
sodium- and potassium-containing medium in five independent experiments performed with five different mitochondrial preparations. Filled circles—
diazoxide, filled triangles—nicorandil. (D) Valinomycin concentration dependency of rat skeletal muscle mitochondria potassium-specific membrane
depolarization. Experimental conditions like in the legends to A and B. The experimental points are averagesF S.D. of differences of membrane potentials
determined in sodium- and potassium-containing medium in three independent experiments performed with three different mitochondrial preparations.
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its action on potassium channels being sensitive to
sulfonylureas–KATP channels. As shown in Fig. 1, panel
C, similarly to diazoxide also nicorandil was able to
stimulate the respiration of L6 cells. For both compounds,
we observed an K1/2 value of about 20 AM. To compare
the effects of KCOs with the potassium-specific iono-
phore valinomycin, we investigated the stimulation of L6
cell respiration by this compound. As shown in Fig. 1,
panel D, the addition of 4 nM valinomycin caused a
nearly four-fold stimulation of cellular respiration. Very
clearly, the addition of the potassium ionophore led to
similar rates of L6 respiration as observed by uncoupling
of mitochondrial oxidative phosphorylation (cf. Fig. 1,
panels A and B). Since the increase of potassium perme-
ability of the plasma membrane leads to hyperpolarisation
and therefore to decrease of ATP consumption by K+/Na+
ATPase, it seemed to us very likely that the observed
stimulatory effects of KCOs on respiration of L6 cells
might be mediated by the increase of potassium perme-
ability of mitochondrial inner membrane.
Next, we investigated the action of the KCOs on the
respiration of isolated skeletal muscle mitochondria. As
Fig. 4. Effects of KCOs on the NAD(P)H fluorescence of isolated skeletal muscle mitochondria. (A) NAD(P)H fluorescence changes by diazoxide in a
potassium-containing medium. Six milligrams of rat skeletal muscle mitochondria (RSM) was added into 1 ml of the potassium-containing medium for
mitochondrial respiration measurements (see Materials and Methods). Additions: 10 mM glutamate + 5 mM malate; diazoxide—50 AM; ADP—2 mM; KCN—
4 mM. (B) NAD(P)H fluorescence changes by diazoxide in a sodium-containing medium. Six milligrams of rat skeletal muscle mitochondria (RSM) was added
into 1 ml of the sodium-containing medium for mitochondrial respiration measurements (see Materials and Methods). Additions like in A. (C) Potassium
opener concentration dependency of rat skeletal muscle mitochondria potassium-specific NAD(P)H redox state changes. Experimental conditions like in the
legends to A and B. The experimental points are averagesF S.D. of differences of mitochondrial NAD(P)H redox state determined in sodium- and potassium-
containing medium in two independent experiments performed with two different mitochondrial preparations. The NAD(P)H redox state (R, in percentage) was
calculated from the individual fluorescence readings ( F) using the formula: R=(( FFTTFB)/( FKCNFTTFB))100%, FTTFBNAD(P)H fluorescence in the
presence of 1.3 AM TTFB; FKCNNAD(P)H fluorescence in the presence of 10 mM glutamate + 5 mM malate and 4 mM KCN. Filled circles—diazoxide,
filled triangles—nicorandil. (D) Valinomycin concentration dependency of rat skeletal muscle mitochondria potassium-specific NADH redox state change.
Experimental conditions like in the legends to A and B. The experimental points are averagesF S.D. of differences of mitochondrial NAD redox state
determined in sodium- and potassium-containing medium in two independent experiments.
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shown in Fig. 2, panel A, diazoxide addition caused an
about four-fold stimulation of resting state respiration. A
slightly lower stimulation of respiration (about three-fold)
was observed with nicorandil (Fig. 2, panel B). From the
dose–response curves of both KCOs, K1/2 values of about
20 AM can be derived. These results are very similar to the
data obtained with the L6 cells.
In further experiments, we investigated the effect of the
KCOs on mitochondrial membrane potential. For these
investigations, we used the potential sensitive fluorescent
dye rhodamine 123. To test for potassium-specific effects of
openers and to account for possible unspecific uncoupling-
related side effects of the drugs [21], we performed identical
experiments in a medium containing 60 mM potassium or
60 mM sodium, respectively. The fluorescent traces of two
typical experiments are shown in Fig. 3, panels A and B.
After addition of the mitochondria, the fluorescence of
rhodamine 123 decreased due to accumulation of the dye
in the mitochondrial matrix space and position-related
fluorescence quenching. In both media containing K+ or
Na+, a similar steady-state fluorescence level was reached.
Thereafter, subsequent additions of diazoxide were per-
formed. While in the sodium-containing medium only very
small fluorescence changes were detected up to a diazoxide
concentration of 180 AM, in the potassium-containing
medium, a considerable fluorescence increase was observed.
The further addition of valinomycin caused in the potas-
sium-containing medium full mitochondrial membrane
depolarization, whereas in the sodium-containing medium,
only the uncoupler TTFB was able to depolarize the
mitochondrial inner membrane. To quantify the changes in
rhodamine 123 fluorescence, we performed a calibration of
fluorescence signals in the sodium-containing medium
using potassium diffusion potentials. To determine the value
of potassium-specific depolarization caused by a certain
amount of opener, we subtracted from the value of mito-
chondrial membrane potential in sodium medium the value
in potassium medium. The results of this procedure for
diazoxide (circles) and nicorandil (triangles) are plotted in
Fig. 3, panel C. Thus, diazoxide leads at saturating concen-
trations of about 100 AM to a maximal depolarization of
about 8 mV, whereas nicorandil concentrations above 100
AM caused a maximal depolarization of 5 mV. An analogue
control experiment performed with the ionophore valino-
mycin is shown in Fig. 3, panel D. In contrast to the
saturation behaviour seen with the applied KCOs, valino-
mycin caused a dose-dependent mitochondrial inner mem-
brane depolarization showing no saturation.
Furthermore, we studied the effects of KCOs on
mitochondrial NAD(P)H fluorescence. Again, we com-
pared the effects of the openers in the potassium-contain-
ing medium with the sodium-containing medium. The
experimental traces are shown in Fig. 4, panels A and
B. Very clearly, diazoxide caused in the potassium-con-
taining medium (panel A) a decrease of the NAD(P)H
fluorescence steady-state level, whereas in sodium-con-
taining medium, almost no effect was detectable. In
analogy to the experiments with mitochondrial membrane
potential, we determined the differences of the opener
effects between the sodium-containing medium and the
potassium-containing medium. In Fig. 4, panel C, we
plotted the potassium-specific decrease of the NAD(P)H
redox state level versus the concentration of diazoxide
(circles) and nicorandil (triangles). In agreement with the
previous data shown for mitochondrial membrane poten-
tial and respiration, nicorandil showed a lower potassium-
Fig. 5. Effects of 5-hydroxydecanoic acid and glibenclamide on the
potassium-specific mitochondrial membrane depolarization by diazoxide.
(A) Diazoxide concentration dependency of rat skeletal muscle mitochon-
dria potassium-specific membrane depolarization. Experimental conditions
like in the legends to Fig. 3A and B. The experimental points are
averagesF S.D. of differences of membrane potentials determined in
sodium- and potassium-containing medium in two independent experi-
ments. Filled circles—control experiments with diazoxide; open circles—
experiments performed in the presence of 500 AM 5-hydroxydecanoic acid;
filled squares—experiments performed in the presence of 30 AM
glibenclamide. (B) Glibenclamide inhibition of potassium-specific depola-
rization of rat skeletal muscle mitochondria induced by 140 AM diazoxide.
Experimental conditions like in the legends to Fig. 3A and B. The
experimental points are averagesF S.D. of differences of membrane
potentials determined in the presence of 140 AM diazoxide in sodium-
and potassium-containing medium in two independent experiments at the
initial glibenclamide concentrations indicated.
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specific decrease of the NAD(P)H redox state level
(10%), whereas diazoxide caused an approximately 20%
decrease. Again, we observed a saturation behaviour for
both openers. In contrast, the ionophore valinomycin
caused a nearly linear decline of the NAD(P)H redox
state level (Fig. 4, panel D).
In further experiments, we investigated the influence of
the known inhibitors of mitoKATP channels glibenclamide
and 5-hydroxydecanoic acid on the observed potassium
opener-induced alterations of mitochondrial oxidative
phosphorylation. In analogy to the experiments shown
in Fig. 3, panel C, we determined the potassium-specific
depolarization by diazoxide in the presence of the differ-
ent blockers. The results of these experiments are shown
in Fig. 5, panel A. While 5-hydroxydecanoic acid at a
concentration of 500 AM inhibited the depolarization only
by about 20% (open circles; cf. to the control experiment,
closed circles), the addition of 30 AM glibenclamide was
sufficient to inhibit the potassium-specific depolarization
of mitochondria by diazoxide almost completely (trian-
gles). As shown in Fig. 5, panel B, we performed similar
titrations at different concentrations of glibenclamide and
were able to determine the K1/2 value for the glibencla-
mide inhibition equal to 5 AM.
To show the direct influx of potassium ions into the
mitochondrial matrix space, we have measured swelling of
rotenone de-energised mitochondria (as decrease of absorb-
ance at 540 nm) in a medium containing KSCN. Because
SCN freely permeates membranes, the swelling rate is
limited by the potassium permeability of the mitochondrial
inner membrane under these conditions. Fig. 6, panel A,
shows that both diazoxide and nicorandil at a concentration
of 100 AM facilitated swelling of rat skeletal muscle
mitochondria approaching approximately half of the vali-
nomycin-induced rate of absorbance decrease. In Fig. 6,
panel B, the concentration dependency of the rate of
absorbance decrease is given. Very clearly, both diazoxide
and nicorandil facilitated swelling in the same concentration
range necessary to observe potassium-specific effects of
both KCOs on oxidative phosphorylation.
4. Discussion
In this study, we have shown that KCOs are able to
modulate mitochondrial oxidative phosphorylation both in
L6 skeletal muscle myoblasts and rat skeletal muscle
mitochondria. We have been able to provide evidence that
the observed effects of KCOs are due to activation of
electrogenic potassium transport through the inner mito-
chondrial membrane. Probably they are caused by a potas-
sium channel that belongs to the family of mitoKATP
channels previously described in liver [6], heart [7], and
brain mitochondria [8,9].
Our conclusion on the presence of mitoKATP channel in
skeletal muscle mitochondria is based on measurements of
respiration, mitochondrial membrane potential, and mito-
chondrial NAD(P)H fluorescence. We have applied the
specific KCOs both in K+ and Na+ experimental media to
proof the strict potassium specificity of our observations.
Therefore, well-known side effects of the applied drugs, like
uncoupling of oxidative phosphorylation [21,22], can be
definitely ruled out. Additionally, we showed at comparable
concentrations direct effects of the applied KCOs on potas-
sium permeability of mitochondrial inner membrane.
Treatment both of L6 skeletal muscle myoblast and
isolated skeletal muscle mitochondria with diazoxide or
nicorandil was concomitant with the increase of oxygen
consumption. These effects were strictly dependent on the
Fig. 6. Effects of KCOs on the swelling of de-energised isolated skeletal
muscle mitochondria. (A) Absorbance changes of skeletal muscle
mitochondria by diazoxide, nicorandil and valinomycin. 1.5 mg of rat
skeletal muscle mitochondria was added to 0.5 ml of a KSCN buffer
containing 1 AM rotenone (see Materials and Methods). Additions:
diazoxide—100 AM, nicorandil—100 AM, valinomycin—10 nM. (B)
Potassium opener concentration dependency of rat skeletal muscle
mitochondria swelling. Experimental conditions like in the legend to A.
Steady-state rates of absorbance changes (obtained 1 min after the addition
of the drug) are plotted versus KCO concentration. The experimental points
are averagesF S.D. of three independent experiments performed with two
different mitochondrial preparations. Filled circles—diazoxide, filled
triangles—nicorandil.
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presence of potassium ions and were blocked by the anti-
diabetic sulfonylurea—glibenclamide—a well-known
blocker of KATP channels excluding the possibility that
weak uncoupling properties of KCOs were responsible for
the observations [21,22]. Furthermore, both diazoxide and
nicorandil caused a potassium-specific depolarization of
mitochondrial potential. These effects are consistent with
an increase of mitochondrial inner-membrane permeability
for potassium ions and its influx into mitochondrial matrix.
Moreover, both substances were able to cause a potassium-
specific decrease of the NAD(P)H fluorescence steady-state
level indicating oxidation of mitochondrial NADH and
facilitated swelling of de-energised mitochondria in a KSCN
buffer. A similar oxidation of mitochondrial NADH upon
KCO treatment and mitoKATP channel activation was pre-
viously reported to occur in cardiac myocytes [23–25].
Additionally, in contrast to the potassium ionophore valino-
mycin, all observed potassium-specific effects of KCOs on
oxidative phosphorylation showed very clearly saturation
behaviour. This makes a potassium-ion specific ionopho-
retic action very unlikely and supports our concept of
mitochondrial potassium channel activation by the inves-
tigated drugs.
Our data suggest that the skeletal muscle mitoKATP
channel has different pharmacological properties in compar-
ison to those described previously for cardiac, liver, and
brain mitochondria. We observed that the skeletal muscle
channel is less sensitive to the mitoKATP blockers gliben-
clamide [7], and 5-hydroxydecanoic acid [26]. Liver [7],
heart [26], and brain [9] mitoKATP channels are blocked by
glibenclamide with a K1/2 ranging from 56 to 62 nM. In
skeletal muscle mitochondria, we were able to determine a
K1/2 value for glibenclamide equal to 5 AM. Moreover, in
contrast to observations with murine C2C12 skeletal myo-
tubes [17], 5-hydroxydecanoic acid at a concentration of
500 AM inhibited mitoKATP channels of isolated rat skeletal
muscle mitochondria only by about 20%. This substance has
been suggested to be a much more potent blocker of
mitoKATP channel, with a K1/2 from 71 to 83 AM in liver
[26], heart [27], and brain mitochondria [9].
In recent work with heart mitochondria [21], it has
been suggested that opening of mitoKATP channels has
little direct effect on respiration, membrane potential, or
Ca2 + uptake but has important effects on matrix and
intermembrane space volumes. Our data with skeletal
muscle mitochondria do not support these conclusions
but show specific effects of KCOs on oxidative phosphor-
ylation in skeletal muscle. This obvious discrepancy could
be caused by a higher density of mitoKATP channels in
skeletal muscle mitochondria in comparison to heart
mitochondria.
What are the consequences of the presence of a
mitoKATP channel in skeletal muscle mitochondria? Recent
observations on the cardiac cells suggest a potential func-
tional role of mitoKATP channel in ischemic precondition-
ing. Similar to heart muscle, ischemic preconditioning was
observed in skeletal muscle [28–30]. This rises the ques-
tion whether the skeletal muscle mitoKATP channel could
play a similar role in ischemic preconditioning of skeletal
muscle.
In summary, the findings presented in this study provide
functional data showing that KCO-activated potassium
transport in skeletal muscle mitochondria is able to modu-
late oxidative phosphorylation most probably due to the
presence of a mitoKATP channel.
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